Immunization Planning and Management Institute, Hebei Provincial Center For Disease Control And Prevention, Shijiazhuang, Hebei, China.
Public Health School, North China University of Science and Technology, Tangshan, Hebei, China.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2387904. doi: 10.1080/21645515.2024.2387904. Epub 2024 Oct 28.
The aim of this study was to analyze the incidence and characteristics of adverse events following immunization (AEFI) with post-licensure vaccines used in Hebei province from 2018 to 2020 and to evaluate the safety of vaccines. All information of AEFI was gained from national adverse event following immunization surveillance system (NAEFISS) in Hebei Province from 2018 to 2020. Descriptive epidemiology method was used to analyze the data about AEFI in Hebei province. Reporting rates of AEFI were calculated by sex, age, city, categories of AEFI, severity of AEFI, reaction categories, etc. A total of 35,999 AEFI were reported through NAEFISS, and the average annual rate was 47.64/100,000 doses. The reporting rates of common adverse reactions and rare adverse reactions were 46.37/100,000 doses and 1.05/100,000 doses. The male-to-female ratio was 1.26:1. Most of the AEFI were concentrated in the ≤1 year age group and were reported in the second quarter and third quarter. The majority of AEFI were reported to be recovered or improved, and about 62% of the AEFI occurred within 24 hours after vaccination. Vaccines associated with the highest reporting rate of AEFI were diphtheria, tetanus and acellular pertussis combined vaccine (DTaP, 170.45/100,000 doses). The reporting rate of allergic rash was found to be the highest in the adverse reactions (0.29/100,000 doses). The majority of AEFI cases were common adverse reactions, while serious rare adverse reactions caused by vaccines were extremely uncommon, and all vaccines used in Hebei Province were safe.
本研究旨在分析河北省 2018 年至 2020 年上市后疫苗接种后不良事件(AEFI)的发生率和特征,并评估疫苗的安全性。所有 AEFI 信息均来自河北省国家疫苗接种后不良事件监测系统(NAEFISS)。采用描述性流行病学方法分析河北省 AEFI 数据。按性别、年龄、城市、AEFI 类别、AEFI 严重程度、反应类别等计算 AEFI 报告率。通过 NAEFISS 报告了 35999 例 AEFI,年均报告率为 47.64/10 万剂。常见不良反应和罕见不良反应的报告率分别为 46.37/10 万剂和 1.05/10 万剂。男女性别比为 1.26:1。大多数 AEFI 集中在≤1 岁年龄组,报告集中在第二季度和第三季度。大多数 AEFI 报告为痊愈或好转,约 62%的 AEFI 发生在接种后 24 小时内。AEFI 报告率最高的疫苗是白喉、破伤风和无细胞百日咳联合疫苗(DTaP,170.45/10 万剂)。不良反应中报告率最高的是过敏性皮疹(0.29/10 万剂)。大多数 AEFI 病例为常见不良反应,而疫苗引起的严重罕见不良反应极为罕见,河北省使用的所有疫苗均安全。